[Refractory anemias]

Area of Science:

• Hematology
• Oncology
• Genetics

Context:

• Myelodysplastic syndromes (MDS), also known as refractory anemia, are a group of clonal hematopoietic stem cell diseases.
• MDS predominantly affects an older population, with a median age of diagnosis in the mid-70s.
• The disease is characterized by ineffective hematopoiesis and cytopenias, despite normo- or hypercellular bone marrow.

Purpose:

• To describe the characteristics, prognosis, and treatment landscape of myelodysplastic syndromes.
• To highlight the evolution of prognostic scoring systems, from the original International Prognostic Scoring System (IPSS) to the Revised IPSS (R-IPSS).
• To outline current therapeutic strategies for MDS, including supportive care and novel agents.

Summary:

• MDS are clonal disorders of the bone marrow leading to cytopenias, primarily affecting elderly individuals.
• Prognosis is determined by patient comorbidities and disease-specific factors, quantified by the IPSS and R-IPSS.
• Treatment approaches range from supportive care and growth factors to targeted therapies like lenalidomide and 5-azacitidine, with allogeneic BMT as an option for select patients.

Impact:

• Accurate prognostication using R-IPSS aids in clinical decision-making and patient counseling.
• The development of novel therapeutic agents has improved outcomes and quality of life for MDS patients.
• Understanding MDS pathogenesis and risk stratification is crucial for advancing treatment strategies and potentially curative options.